The Gila monster’s venomous saliva contains a molecule called exendin-4 that extends insulin production by mimicking a natural hormone, enabling efficient sugar processing after large meals.
Introduction
Gila monsters (Heloderma suspectum) are one of the few venomous lizards in the world, inhabiting the deserts of the southwestern United States and northern Mexico. Life in these arid environments is feast or famine. When food is available, these lizards gorge themselves—sometimes consuming up to half their body weight in a single meal.
To survive long periods between meals, they must make the most of the energy they get. This means carefully regulating how sugar enters their cells and is stored or used. Their ability to do this efficiently, using a compound in their saliva, is a life-sustaining —and an inspiration for treating diabetes in humans.
The Strategy
Like all vertebrates, Gila monsters convert carbohydrates into —a sugar used by cells for energy. Normally, after a meal, the body produces to help move glucose from the blood into cells. A secondary , called GLP-1 (glucagon-like peptide-1), boosts insulin production. However, in most animals, GLP-1 breaks down quickly and only offers a brief signal.
But in the Gila monster’s saliva, there’s a version of this hormone called exendin-4. It’s remarkably stable and sticks around much longer in the bloodstream. This allows the to continue releasing insulin over extended periods—hours rather than minutes. This is especially helpful after a large meal, helping the lizard avoid sugar spikes and steadily draw energy from its food over time.
Exendin-4 functions similarly to GLP-1 by activating the same cellular receptors. However, its structure protects it from the enzymes that usually break down GLP-1. As a result, it provides longer-lasting effects with no need for constant replenishment. This adaptation ensures the Gila monster can stretch the energetic benefits of a rare meal for as long as possible.
"[E]xendin-4 was discovered in 1992 in the gila monster, after a researcher noticed the gila’s venom caused the pancreas of bitten victims to swell."
The Potential
This strategy has already changed human lives. In 1992, scientists discovered exendin-4 and began developing synthetic versions for human use. Today, this molecule is the basis for several medications used to treat type 2 diabetes, including exenatide (Byetta). These drugs help diabetics produce more insulin for longer periods without triggering blood sugar crashes. They also encourage weight loss by slowing digestion and increasing satiety after meals.
By studying the biochemistry of a desert-dwelling lizard, researchers have unlocked a sustainable, nature-inspired way to regulate blood sugar—without needing constant drug delivery. This is at its best: solving a human challenge by emulating a strategy refined through evolution.
Related Innovation
AI on AskNature
This page was produced in part with the assistance of AI, which is allowing us to greatly expand the volume of content available on AskNature. All of the content has been reviewed for accuracy and appropriateness by human editors. To provide feedback or to get involved with the project, contact us.